English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Katherine A Minson1,2, Deborah DeRyckere1 and Douglas K Graham1* 1Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University, USA 2Department of Pediatrics, Atlanta, GA, USA *Corresponding author: Douglas K Graham, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, USA, Tel: (404) 727-5002; Fax: (404) 727-4455; E-mail: Douglas.Graham@choa.org

The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises